An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
† Indicates status has not been verified in more than two years